+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

INmune Bio

(NASDAQ:INMB)

Intraday

$10.49

-0.28[-2.60%]

After-Hours

$10.49

0[0.00%]

Perks Buy Compare Brokers

$10.49

-0.28[-2.60%]

At close: May 9

$10.49

0[0.00%]

PreMarket: 5:35PM EDT

Q1 2024 Earnings were released on Thu May 9th, after the market close

The most recent conference call was at 16:30 PM, 1 day ago Click to view past webcast

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for INmune Bio Stock (NASDAQ:INMB)

INmune Bio Stock (NASDAQ: INMB)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, May 09, 2024

INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
Benzinga Newsdesk - 13 hours ago

Tuesday, April 30, 2024

INmune Bio Provides Update On Two Patients From Phase 1b Alzheimer's Disease Trial Receiving XPro Under Compassionate Use; Says 'Reports from the primary care physicians indicate that XPro has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients.'
Benzinga Newsdesk - Apr 30, 2024, 8:06AM

Monday, April 29, 2024

INmune Bio Completes First Cohort And Initiates Second Cohort Of Phase 1/2 Study Of INKmune Natural Killer Cell Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer
Benzinga Newsdesk - Apr 29, 2024, 8:08AM

Thursday, April 25, 2024

INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation
Benzinga Newsdesk - Apr 25, 2024, 4:56PM
INmune Bio Announces $9.7M Registered Direct Offering Of 986,000 Shares And Warrants At $9.84/Share And Accompanying Warrant
Benzinga Newsdesk - Apr 25, 2024, 9:01AM

Tuesday, April 23, 2024

INmune Bio Announces 24-Month Stability Validation Of XPro For Phase III Readiness And Commercial Supply Chain Modeling & Development Of Novel Immunogenicity Assay
Benzinga Newsdesk - Apr 23, 2024, 8:05AM

Monday, April 22, 2024

INmune Bio Inc. Raises ~$4.8M In Gross Proceeds Through Registered Direct Offering With Officers, Employees And Directors Purchasing ~20% Of The Offering
Benzinga Newsdesk - Apr 22, 2024, 8:06AM

Monday, April 08, 2024

INmune Bio Inc. Presents Data On INB03's Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024
Benzinga Newsdesk - Apr 8, 2024, 8:16AM

Thursday, March 28, 2024

INmune Bio: Q4 Earnings Insights
Benzinga Insights - Mar 28, 2024, 4:20PM
INmune Bio Q4 EPS $(0.47) Misses $(0.44) Estimate, Sales $28.00K Miss $40.00K Estimate
Benzinga Newsdesk - Mar 28, 2024, 4:20PM
Earnings Scheduled For March 28, 2024
Benzinga Insights - Mar 28, 2024, 5:24AM

Wednesday, March 27, 2024

A Preview Of INmune Bio's Earnings
Benzinga Insights - Mar 27, 2024, 2:01PM

Tuesday, March 05, 2024

INmune Bio Reports Significant EEG Improvement In Alzheimer's Patients Treated With XPro
Benzinga Newsdesk - Mar 5, 2024, 8:02AM

Tuesday, January 30, 2024

INmune Bio Announces FDA Removal Of Clinical Hold For Alzheimer's Disease Program
Benzinga Newsdesk - Jan 30, 2024, 8:04AM

Monday, January 22, 2024

On Jan 16, Elevai Labs Inc Entered Into A License Agreement With INmune Bio, Inc.; INmune Granted The Co Certain Worldwide Exclusive And Non-Exclusive License Rights To Develop, Manufacture, And Commercialize INmunes's EMx Technology
Benzinga Newsdesk - Jan 22, 2024, 12:09PM

Tuesday, January 16, 2024

Why Elevai Labs Stock Is Trading Higher
Erica Kollmann - Jan 16, 2024, 12:41PM
ELEVAI Labs Signs Exclusive Worldwide Manufacturing Agreement And License Agreement With INmune Bio Granting ELEVAI A License To Use INmune's EMx Technology
Benzinga Newsdesk - Jan 16, 2024, 8:40AM

Tuesday, January 02, 2024

INmune Bio Dosed The First Patient In The Phase 1/2 Trial Of INKmune In Men With Metastatic Castration-resistant Prostate Cancer
Benzinga Newsdesk - Jan 2, 2024, 8:05AM

Monday, December 18, 2023

INmune Bio On Track To Complete Enrollment Of Phase II Clinical Trial In Patients With Early Alzheimer's Disease And Biomarkers Of Inflammation In 2024; FDA Said U.S. Phase II Trial Remains On Full Clinical Hold Pending Additional Information Request
Benzinga Newsdesk - Dec 18, 2023, 4:04PM

Wednesday, November 29, 2023

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
Benzinga Newsdesk - Nov 29, 2023, 8:03AM

Monday, November 27, 2023

INmune Bio Has Received European Medicines Agency's Authorized Decision In France And Spain For Phase 2 Clinical Trial Of XPro For Early Alzheimer's Disease
Benzinga Newsdesk - Nov 27, 2023, 8:12AM

Wednesday, November 15, 2023

INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer's Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive
Benzinga Newsdesk - Nov 15, 2023, 9:01AM

Wednesday, November 01, 2023

INmune Bio Q3 2023 Gaap EPS $(0.48) Misses $(0.41) Estimate, Sales $43.00K Down From $98.00K YoY
Benzinga Newsdesk - Nov 1, 2023, 4:31PM
Earnings Scheduled For November 1, 2023
Benzinga Insights - Nov 1, 2023, 7:19AM

Tuesday, October 31, 2023

INmune Bio Inc. Patent Claims Covering INB16 Cell Line And INKmune Therapeutic Composition given Favorable Patentability Opinion By International Search Authority
Benzinga Newsdesk - Oct 31, 2023, 8:03AM

Monday, October 30, 2023

INmune Bio Inc. Presents Preclinical Data At SITC 2023 Showing INB03 Is An Innate Immune Check Point Inhibitor That Downregulates SIRPα
Benzinga Newsdesk - Oct 30, 2023, 9:08AM

Tuesday, October 17, 2023

INmune Bio Inc. To Present New Biomarker And Feasibility Data From Phase 1b Study Supporting Use Of XPro To Treat Alzheimer's Disease At Clinical Trials On Alzheimer's Disease Conference Oct. 24-27
Benzinga Newsdesk - Oct 17, 2023, 8:01AM

Tuesday, September 05, 2023

INmune Bio Inc. Announces Approval Of Clinical Trial Application By The U.K. Medicines And Healthcare Products Regulatory Agency For Phase 2 Clinical Trial In Alzheimer's Disease
Happy Mohamed - Sep 5, 2023, 8:03AM

Monday, August 07, 2023

INmune Bio Q2 EPS $(0.36) Beats $(0.40) Estimate, Sales $46.00K Up From $16.00K YoY
Benzinga Newsdesk - Aug 7, 2023, 4:22PM
Earnings Scheduled For August 7, 2023
Benzinga Insights - Aug 7, 2023, 4:12AM

Friday, August 04, 2023

Earnings Outlook For INmune Bio
Benzinga Insights - Aug 4, 2023, 4:01PM

Tuesday, July 11, 2023

INmune Bio Reveals New Findings, Says Analysis Of MRI Scans In Participants From Phase 1B Study Shows That Novel Gray Matter Biomarker Improved Following Three Months Of Treatment With XPro1595
Benzinga Newsdesk - Jul 11, 2023, 8:09AM

Monday, July 10, 2023

INmune Bio Inc. Announces Data Presented At The 16th European Meeting On Glial Cells In Health And Disease Shows That XPro Promotes Remyelination By Affecting Astroglial And Microglial Biology
Happy Mohamed - Jul 10, 2023, 4:01PM

Tuesday, June 13, 2023

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease
Johnny Rice - Jun 13, 2023, 8:48AM

Thursday, June 01, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Benzinga Insights - Jun 1, 2023, 11:00AM
Baird Initiates Coverage On INmune Bio with Outperform Rating, Announces Price Target of $16
Benzinga Newsdesk - Jun 1, 2023, 4:29AM

Monday, May 08, 2023

INmune Bio shares are trading higher after the FDA cleared the company's Investigational New Drug application for INKmune.
Benzinga Newsdesk - May 8, 2023, 11:58AM
INmune Bio, Inc. Announces FDA Clearance Of IND Application For INKmune For A Phase I/II Trial In Metastatic Castration-Resistant Prostate Cancer
Benzinga Newsdesk - May 8, 2023, 8:05AM

Wednesday, May 03, 2023

INmune Bio Q1 EPS $(0.36) Misses $(0.02) Estimate, Sales $38.00K Down From $163.00K YoY
Benzinga Newsdesk - May 3, 2023, 5:43PM
INmune Bio Q1 EPS $(0.36) May Not Compare To $(0.02) Estimate
Happy Mohamed - May 3, 2023, 5:06PM

Tuesday, May 02, 2023

INmune Bio's Earnings Outlook
Benzinga Insights - May 2, 2023, 4:01PM

Wednesday, April 19, 2023

XPro1595 Improves Outcomes In A Mouse Model Of Traumatic Brain Injury-Induced Alzheimer's Disease
Happy Mohamed - Apr 19, 2023, 8:34AM

Monday, April 03, 2023

INmune Bio, Inc. Announces Submission Of Investigational New Drug Application For INKmune To FDA For Treatment Of Metastatic Castration-Resistant Prostate Cancer
Benzinga Newsdesk - Apr 3, 2023, 9:02AM

Wednesday, March 08, 2023

INmune Bio Earnings Perspective: Return On Capital Employed
Benzinga Insights - Mar 8, 2023, 9:47AM

Friday, March 03, 2023

INmune shares are trading lower after the company reported Q4 sales results were lower year over year.
Michael Horton - Mar 3, 2023, 10:49AM

Thursday, March 02, 2023

INmune Bio Q4 EPS $(0.32) Beats $(0.48) Estimate, Sales $97.00K Down From $163.00K YoY
Benzinga Newsdesk - Mar 2, 2023, 4:12PM
Earnings Scheduled For March 2, 2023
Benzinga Insights - Mar 2, 2023, 4:37AM

Wednesday, March 01, 2023

Earnings Preview: INmune Bio
Benzinga Insights - Mar 1, 2023, 12:01PM

Thursday, February 09, 2023

Dow Jumps 250 Points; US Jobless Claims Increase Last Week
Lisa Levin - Feb 9, 2023, 10:42AM

Wednesday, February 08, 2023

Nasdaq Tumbles 150 Points; Crude Oil Up 1.5%
Lisa Levin - Feb 8, 2023, 1:43PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved